Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Harvard Business School
Dow
Medtronic
Boehringer Ingelheim

Last Updated: May 27, 2022

CLINICAL TRIALS PROFILE FOR KEFLEX


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Keflex

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00300092 ↗ Pediatric Fingertip Injuries:Are Antibiotics Required? Completed Children's Hospital Los Angeles Phase 2 2000-09-01 Study objective: Fingertip injuries are common in the pediatric population. Considerable controversy exists about whether prophylactic antibiotics are necessary after repair of such injuries. Our goals were to estimate the rate of bacterial infection among pediatric patients with distal fingertip injuries overall and to compare the rate of bacterial infections among subgroups treated with and without prophylactic antibiotics. Methods: This was prospective randomized control study of pediatric patients presenting to an urban children's hospital with trauma to the distal fingertip requiring repair. Patients were randomized to two groups: those receiving prophylactic antibiotics (Cephalexin) and those who did not receive antibiotic therapy. Repairs were performed in a standardized fashion and all patients were re-evaluated in the same emergency department in 48 hours and by phone 7 days later. The primary outcome of this study was the incidence of infection.
NCT00352612 ↗ Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections Completed Johns Hopkins University Phase 4 2006-09-01 The purpose of this study is to help define the role of antibiotics in the treatment of pediatric skin infections caused by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). The investigators hypothesize that treatment with cephalexin, a penicillin-like antibiotic to which CA-MRSA would be expected to be resistant, does not result in poorer outcomes than treatment with clindamycin, an antibiotic to which CA-MRSA is most often susceptible.
NCT00352612 ↗ Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections Completed Thrasher Research Fund Phase 4 2006-09-01 The purpose of this study is to help define the role of antibiotics in the treatment of pediatric skin infections caused by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). The investigators hypothesize that treatment with cephalexin, a penicillin-like antibiotic to which CA-MRSA would be expected to be resistant, does not result in poorer outcomes than treatment with clindamycin, an antibiotic to which CA-MRSA is most often susceptible.
NCT00352612 ↗ Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections Completed Aaron Chen Phase 4 2006-09-01 The purpose of this study is to help define the role of antibiotics in the treatment of pediatric skin infections caused by community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). The investigators hypothesize that treatment with cephalexin, a penicillin-like antibiotic to which CA-MRSA would be expected to be resistant, does not result in poorer outcomes than treatment with clindamycin, an antibiotic to which CA-MRSA is most often susceptible.
NCT00676130 ↗ Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients Completed Brigham and Women's Hospital N/A 2007-05-01 The primary aim of this study is to quantify the effectiveness of Bactrim as additional therapy for the treatment of uncomplicated cellulitis in adults, by comparing: standard therapy plus Bactrim, versus standard therapy plus placebo. The primary hypothesis of this study is that, in light of increasing CA-MRSA prevalence, subjects treated with standard therapy plus Bactrim will have higher cure rates than those treated with standard therapy plus placebo.
NCT00957827 ↗ Prophylactic Use of Antibiotics for Through and Through Lacerations of the Lip Terminated University of Pennsylvania N/A 2009-08-01 Facial lacerations are a commonly encountered problem in the emergency department. Despite this, few original articles have been written concerning the management of lacerations of the lip which communicate with the oral cavity. Specifically, no study has been able to definitively show whether the use of antibiotics for these wounds decreases the infection rate. These cutaneous wounds are a unique type of laceration because they are continuously contaminated with oropharyngeal flora. Contaminated wounds result in larger, less cosmetic scars. Scars which involve the face have been shown to have a negative psychological impact. In this study, the investigators aim to determine whether the use of antibiotics decrease the rate of infection in lacerations of the lip which communicate with the oral cavity. Patients will be randomized to one of two currently practiced therapies. Patients will receive either cephalexin or no treatment following the repair of their through-and-through lip lacerations to determine whether antibiotics decrease the infection rate in these wounds.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Keflex

Condition Name

Condition Name for Keflex
Intervention Trials
Healthy Volunteers 4
Infections, Respiratory Tract 3
Anti-Infective Agents 3
Urinary Tract Infections 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Keflex
Intervention Trials
Infections 6
Infection 5
Urinary Tract Infections 3
Communicable Diseases 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Keflex

Trials by Country

Trials by Country for Keflex
Location Trials
United States 15
Mexico 8
Austria 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Keflex
Location Trials
Pennsylvania 3
California 3
Michigan 2
Massachusetts 1
Maryland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Keflex

Clinical Trial Phase

Clinical Trial Phase for Keflex
Clinical Trial Phase Trials
Phase 4 5
Phase 2 3
Phase 1 14
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Keflex
Clinical Trial Phase Trials
Completed 19
Recruiting 3
Terminated 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Keflex

Sponsor Name

Sponsor Name for Keflex
Sponsor Trials
Investigacion Farmacologica y Biofarmaceutica, S.A. de C.V. 5
Eli Lilly and Company 5
GlaxoSmithKline 3
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Keflex
Sponsor Trials
Other 27
Industry 15
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Mallinckrodt
McKinsey
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.